drugset / Trial / NCT03987308
Comparing the Efficacy and Safety Between Continuous Subcutaneous Beinaglutide and CSII for Newly Diagnosed T2DM Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
The efficacy, safety and post-treatment disease control will be compared between groups of continuous subcutaneous Beinaglutide infusion and continuous subcutaneous insulin infusion (CSII) in adult patients with newly diagnosed type 2 diabetes.
Timeline
- Start
- 2019-07-02
- Primary completion
- 2025-09
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Beinaglutide | Protein / enzyme biologic | — | Subcutaneous |
| Comparator | insulin aspart | Protein / enzyme biologic | — | Subcutaneous |